These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17463074)

  • 1. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study.
    Zabad RK; Metz LM; Todoruk TR; Zhang Y; Mitchell JR; Yeung M; Patry DG; Bell RB; Yong VW
    Mult Scler; 2007 May; 13(4):517-26. PubMed ID: 17463074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
    Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
    Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
    Zhao Y; Traboulsee A; Petkau AJ; Li D
    Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
    Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
    Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental models of neuroprotection relevant to multiple sclerosis.
    Yong VW; Giuliani F; Xue M; Bar-Or A; Metz LM
    Neurology; 2007 May; 68(22 Suppl 3):S32-7; discussion S43-54. PubMed ID: 17548566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.
    Gauthier SA; Glanz BI; Mandel M; Tsagkaropoulos A; Neema M; Stankiewicz J; Arora A; Duan Y; Liptak Z; Egorova S; Buckle GJ; Bakshi R; Guttmann CR; Khoury SJ; Weiner HL
    J Neurol Sci; 2009 Sep; 284(1-2):116-9. PubMed ID: 19428028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients.
    Rumbach L; Racadot E; Armspach JP; Namer IJ; Bonneville JF; Wijdenes J; Marescaux C; Herve P; Chambron J
    Mult Scler; 1996 Feb; 1(4):207-12. PubMed ID: 9345436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.
    Bonavita S; Dinacci D; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Bresciamorra V; Orefice G; Paciello M; Coniglio G; Di Costanzo A; Valentino P; Patti F; Salemi G; Simone I; Tedeschi G
    Neurol Sci; 2006 Sep; 27 Suppl 5():S365-8. PubMed ID: 16998722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
    Ory S; Debouverie M; Le Page E; Pelletier J; Malikova I; Gout O; Roullet E; Vermersch P; Edan G
    Rev Neurol (Paris); 2008 Dec; 164(12):1028-34. PubMed ID: 18808781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
    Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
    Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
    Minagar A; Adamashvilli I; Jaffe SL; Glabus MF; Gonzalez-Toledo E; Kelley RE
    Ann N Y Acad Sci; 2005 Jun; 1051():111-20. PubMed ID: 16126950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.
    Farez MF; Correale J
    Arch Neurol; 2011 Oct; 68(10):1267-71. PubMed ID: 21670384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of multiple sclerosis with the pregnancy hormone estriol.
    Sicotte NL; Liva SM; Klutch R; Pfeiffer P; Bouvier S; Odesa S; Wu TC; Voskuhl RR
    Ann Neurol; 2002 Oct; 52(4):421-8. PubMed ID: 12325070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.
    Kaiser CC; Shukla DK; Stebbins GT; Skias DD; Jeffery DR; Stefoski D; Katsamakis G; Feinstein DL
    J Neuroimmunol; 2009 Jun; 211(1-2):124-30. PubMed ID: 19446890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.